Identity
Aviptadil is a synthetic vasoactive intestinal peptide studied in several clinical settings.
Selected study only; not a complete clinical review.
Peptide library
VIP
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The controlled TESICO trial stopped for futility and did not establish clinical benefit in COVID-19 respiratory failure. Neither mechanistic vasodilation nor a different formulation overrides that result.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Adults hospitalized with COVID-19 hypoxemic respiratory failure; TESICO trial.
What the sources found
Intravenous aviptadil did not significantly improve the primary 90-day outcome; the trial stopped for futility.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
Aviptadil is a synthetic vasoactive intestinal peptide studied in several clinical settings.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- This critically ill population does not establish safety for intranasal or other uses.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Intravenous aviptadil did not significantly improve the primary 90-day outcome; the trial stopped for futility.
Selected study only; not a complete clinical review.
Adverseeffects
This critically ill population does not establish safety for intranasal or other uses.
Selected study only; not a complete clinical review.
References
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. 2023.
PMID: 37348524
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.